<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04054115</url>
  </required_header>
  <id_info>
    <org_study_id>1000060394</org_study_id>
    <nct_id>NCT04054115</nct_id>
  </id_info>
  <brief_title>Acute Effects of the Prostaglandin (Alprostadil) on Cerebral and Pulmonary Flow</brief_title>
  <acronym>Alprostadil</acronym>
  <official_title>The Acute Effects of the Prostaglandin (Alprostadil) on Cerebral and Pulmonary Flow After the Bidirectional Cavopulmonary Connection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The second stage operation towards single ventricle palliation is 'bidirectional&#xD;
      cavopulmonary connection' (BCPC). The superior vena cava is connected to the pulmonary&#xD;
      artery, diverting 'blue' blood from the upper body (including the brain) to the lungs. A&#xD;
      successful BCPC requires sufficient and easy blood flow through the lungs. Alprostadil is the&#xD;
      synthetic form of prostaglandin (hormone that causes dilation of blood vessels) and has been&#xD;
      shown to increase blood flow in the brain hence increasing blood flow to the lungs after&#xD;
      BCPC, potentially useful in managing children post BCPC with low flow to the lungs and thus&#xD;
      poor oxygenation. This study propose to investigate acute effects of Alprostadil on different&#xD;
      blood vessels after BCPC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients with a bidirectional Glenn in their Pre-Fontan evaluation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral blood flow</measure>
    <time_frame>will be measured 30 minutes to 40 minutes after infusion of alprostadil</time_frame>
    <description>Cerebral blood flow</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline cardiac catheterization under GA. (Standard of Care, SOC)&#xD;
Transfer patient to MRI unit&#xD;
Baseline MRI&#xD;
Obtain ABG for pCO2 from existing femoral arterial access.&#xD;
Repeat pressure measurements with existing catheters at the SVC, RA and Aorta.&#xD;
MRI phase contrast imaging for flow measurements(SOC).&#xD;
During the MRI, Alprostadil infusion will be started and titrated to the target dose 0.1mcg/kg/min, provided there is a less than 20% drop in blood pressure from baseline.&#xD;
Post alprostadil infusion&#xD;
1ml blood sample taken from existing femoral venous access for prostaglandin level.&#xD;
Repeat pressure measurements with existing catheters left at the SVC, RA and Aorta.&#xD;
Repeat MRI flow measurements&#xD;
7.Return to cath lab if further intervention required. 8.Recovery and monitoring for 4 to 6 hours prior to discharge(SOC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprostadil 5 MCG Injection</intervention_name>
    <description>During the MRI, Alprostadil infusion will be started and titrated to the target dose, ensuring there is a less than 20% drop in blood pressure from baseline. Repeat pressure and MRI flow measurements once Alprostadil reaches 0.1mcg/kg/min.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:• BCPC patients at time of routine pre-Fontan assessment: Cardiac&#xD;
        catheterization and cardiac magnetic resonance imaging (CMR)&#xD;
&#xD;
        • Patients between the ages of 1 and 6 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are hypersensitive to this product or to any ingredient in its&#xD;
             formulation.&#xD;
&#xD;
          -  Patients with seizure disorders or coagulopathies.&#xD;
&#xD;
          -  Patients with abnormal kidney function.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajiv Chaturvedi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajiv Chaturvedi, MD</last_name>
    <phone>416-813-7654</phone>
    <phone_ext>206141</phone_ext>
    <email>rajiv.chaturvedi@sickkids.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>L4K4x6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajiv Chaturvedi, MD</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>206141</phone_ext>
      <email>rajiv.chaturvedi@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>David Faraoni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vannessa Chin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars GrosseWortmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Lam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sok-Leng Kang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Rajiv Chaturvedi</investigator_full_name>
    <investigator_title>Staff Cardiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprostadil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

